TYK2 Inhibitor Envudeucitinib Shows Durable Skin Clearance, QoL Gains: Poster

Key Takeaways

• Envudeucitinib 40 mg BID met psoriasis treat-to-target thresholds for PASI, BSA, and DLQI at week 52.

• Over 80% of patients achieved PASI ≤1, and more than half reported DLQI 0.

• Data support envudeucitinib’s potential as an effective oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.

Envudeucitinib, an investigational selective allosteric TYK2 inhibitor, showed sustained achievement of clinically meaningful treat-to-target outcomes in patients with moderate-to-severe plaque psoriasis, according to 52-week data presented at Winter Clinical Hawaii 2026.

The analysis, captured in a poster by April Armstrong, MD, and colleagues, included results from the STRIDE phase 2 trial  and its ongoing open-label extension (OLE) study, assessing the 40 mg twice-daily (BID) dose. At week 52, patients receiving envudeucitinib 40 mg BID reported consistent improvements across PASI, BSA, and DLQI metrics. Specifically, 81.3% of patients achieved PASI ≤1, 75.0% achieved PASI ≤2, and 60.0% achieved BSA ≤1%. For quality-of-life measures, 67.5% reported DLQI 0/1 and 52.5% achieving DLQI 0.

"Treatment with envudeucitinib 40 mg BID led to rapid and sustained achievement of stringent treat-to-target thresholds in patients with moderate-to-severe plaque PsO," the authors wrote. "Sustained improvements in both skin clearance and QoL were observed from week 12 through week 52, reflecting consistent benefits across clinical and patient-reported outcomes. These results demonstrated sustained efficacy over time, reinforcing envudeucitinib’s potential as a differentiated next-generation oral TYK2 inhibitor."

Source: Armstrong A, Ehst B, Hawkes J, Ma G, Klyashkin Y, Hitraya E, Papp K. Achievement of Treat-to-Target Thresholds with Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE. Presented at: Winter Clinical Hawaii 2026.